The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...

The risk of developing RDS was significantly increased among newborns born to mothers with confirmed COVID-19 infection during pregnancy.

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

Acute respiratory distress syndrome (ARDS) is a neutrophil-dominant disorder with no effective pharmacological therapies. While the cyclin-dependent kinase inhibitor AT7519 induces neutrophil ...

Background: The longitudinal course of patients with pediatric acute respiratory distress syndrome (PARDS) is not well described. In this study, we describe the oxygenation index (OI) and oxygen ...

To establish a prediction nomogram for early prediction of neonatal acute respiratory distress syndrome (NARDS). Methods: This is a retrospective cross-sectional study conducted between January 2021 ...

medschl.cam.ac.uk The reported incidence of ARDS is highly variable (2.5%–19% of intensive care unit (ICU) patients) and varies depending on study patient population used. We undertook a 6-month, ...

InflaRx (IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

Objective: To systematically review the effects of recruitment maneuvers on patients with acute respiratory distress syndrome. Methods: This systematic review and meta-analysis using the PICO ...